BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).
B. Melichar
Consultant or Advisory Role - Roche
Honoraria - GlaxoSmithKline; Novartis; Roche
S. Bracarda
Consultant or Advisory Role - Bayer (U); GlaxoSmithKline (U); Novartis (U); Pfizer
Honoraria - Novartis
V. Matveev
No relevant relationships to disclose
I. Rusakov
No relevant relationships to disclose
A. Kaprin
No relevant relationships to disclose
A. Zyryanov
No relevant relationships to disclose
R. Janciauskiene
Honoraria - Roche
E. Fernebro
No relevant relationships to disclose
G. H. Mickisch
Consultant or Advisory Role - AstraZeneca; Bayer; GlaxoSmithKline; Roche; Takeda; Wyeth
Honoraria - Astellas Pharma; AstraZeneca; Bayer; GlaxoSmithKline; Pfizer; Roche; Sanofi ; Takeda; Wyeth
M. E. Gore
Consultant or Advisory Role - Roche
Honoraria - Roche
A. Schulze
Consultant or Advisory Role - PAREXEL International
S. Jethwa
Employment or Leadership Position - Roche
Stock Ownership - Roche
V. Sneller
Employment or Leadership Position - Roche
P. Mulders
No relevant relationships to disclose
J. Bellmunt
Consultant or Advisory Role - Bayer; Novartis; Pfizer; Roche
Stock Ownership - Bayer; Novartis; Pfizer; Roche